Bruckner Group Founder to Present at New York Society of Security Analysts.Business Editors/Health/Medical Writers BIOWIRE2K BOSTON--(BUSINESS WIRE)--Feb. 5, 2003 The Bruckner Group's David Balekdjian Discusses Major Paradigm Shift A dramatic change in methodology or practice. It often refers to a major change in thinking and planning, which ultimately changes the way projects are implemented. For example, accessing applications and data from the Web instead of from local servers is a paradigm shift. See paradigm. in the Pharmaceutical and Biotechnology Industries at Upcoming NYSSA Nyssa (nĭs`ə), name of several ancient cities devoted to the worship of Dionysus. The best known of them is a town of Cappadocia, Asia Minor, near the Halys (now the Kizil Irmak) River. It was the residence of St. Gregory of Nyssa. Event The Bruckner Group, a strategy consulting firm Noun 1. consulting firm - a firm of experts providing professional advice to an organization for a fee consulting company business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a engaged exclusively in the pharmaceutical, biotechnology, and medical device industries, today announced that Founding Partner, David Balekdjian will speak at an upcoming New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Society of Security Analysts (NYSSA) event entitled Outcomes-Based Access: Shaking Up the Pharma and Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. Industries. The event will take place at The American Management Association, 1601 Broadway, New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , NY on February 26, 2003. For more information on attending the NYSSA event, please contact RJ Bardsley at the Miller Consulting Group (617.262.1800 ext. 225) or to register directly, visit the NYSSA website at www.nyssa.org/events/. At the NYSSA event, Balekdjian will discuss Outcomes-Based Access, an aggressive and comprehensive new effort by managed care organizations to control drug costs resulting in the rejection of 40% of new drugs submitted for formulary formulary /for·mu·lary/ (for´mu-lar?e) a collection of recipes, formulas, and prescriptions. National Formulary see under N. for·mu·lar·y n. approval. Under Outcomes-Based Access, managed care organizations are restricting preferential formulary inclusion to only those new drug products that can unambiguously demonstrate a compelling value proposition through complex pharmacoeconomic models. The value proposition must show how new drug treatments produce equal or better patient outcomes (medical results) than current treatments while at the same time lowering overall treatment costs. Drugs rejected for formulary inclusion are available to patients, if at all, on a strictly limited basis or if the patient pays the full retail cost of the drug. "Collectively, these changes are already impacting pharmaceutical industry revenues and profitability and forcing drug companies to fundamentally change how they do business," said Balekdjian. "As a result of Outcomes-Based Access, managed care organizations are rejecting an average of 40% of new drugs submitted for formulary approval, increasing restrictions on physician prescribing practices, limiting drug companies' ability to market to physicians, and working to reduce patient demand for expensive branded drug products." NYSSA's program will provide investment professionals and practitioners in the pharmaceutical, biotech, managed care, and related industries with a unique opportunity to network with their counterparts in the healthcare industry and to leave with an action plan for creating effective drug development and investment strategies. The program is supported, in part, by Pharmaceutical Executive magazine. About The New York Society of Security Analysts NYSSA is a not-for-profit educational organization with over 8,500 members that is committed to the education, inspiration and advancement of investment professionals. The Society's objectives are to provide the premier forum for the exchange of information among investment professionals, corporate management and the investing public; to maintain a continuing education continuing education: see adult education. continuing education or adult education Any form of learning provided for adults. In the U.S. the University of Wisconsin was the first academic institution to offer such programs (1904). program; and to encourage high standards of ethics and professional conduct, integrity and professionalism. NYSSA is the largest of the more than 115 societies worldwide that comprise the Association for Investment Management and Research(R) (AIMR AIMR See Association for Investment Management and Research (AIMR). (R)), which has nearly 58,000 members. For further information, visit www.nyssa.org. About The Bruckner Group The Bruckner Group Inc. (BGI BGI Barclays Global Investors BGI Bainbridge Graduate Institute BGI Bureau Gravimétrique International BGI Borland Graphic Interface (File Name Extension) BGI Bridgetown, Barbados - Grantley Adams International ) is a strategy consulting firm serving the pharmaceutical, biotechnology, and medical device companies. The firm provides competitive strategic advice and creative, actionable solutions based on data-intensive analyses. BGI helps clients address a variety of strategic management issues including product and corporate competitive positioning, strategic marketing, and corporate development. BGI's clients include leading pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . For more information about The Bruckner Group please visit www.brucknergroup.com or call 781.944.4454. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion